Fielmann Aktiengesellschaft (FLMNF)
USD 46.75
(0.0%)
USD 46.75
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 403.8 Million EUR | 39.93% |
| 2022 | 348.54 Million USD | -22.06% |
| 2021 | 397.2 Million USD | 18.7% |
| 2020 | 380.97 Million USD | -7.46% |
| 2019 | 386.25 Million USD | 38.64% |
| 2018 | 296.92 Million EUR | 1.5% |
| 2017 | 292.53 Million EUR | 3.27% |
| 2016 | 283.26 Million EUR | 1.11% |
| 2015 | 280.15 Million EUR | 5.47% |
| 2014 | 265.63 Million EUR | 12.77% |
| 2013 | 235.56 Million EUR | 8.27% |
| 2012 | 217.57 Million EUR | 3.3% |
| 2011 | 210.62 Million EUR | 4.02% |
| 2010 | 202.47 Million EUR | 2.43% |
| 2009 | 197.68 Million EUR | 5.74% |
| 2008 | 186.95 Million EUR | 13.47% |
| 2007 | 164.75 Million EUR | -47.8% |
| 2006 | 315.59 Million EUR | -46.97% |
| 2005 | 595.18 Million EUR | 967.71% |
| 2004 | 55.74 Million EUR | -21.4% |
| 2003 | 70.91 Million EUR | 6.34% |
| 2002 | 66.68 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 114.87 Million EUR | 227.05% |
| 2024 Q2 | 118.31 Million EUR | 5.13% |
| 2023 FY | - EUR | 39.93% |
| 2023 Q3 | 137.79 Million EUR | 23.03% |
| 2023 Q4 | 35.12 Million EUR | -74.51% |
| 2023 Q1 | 114.37 Million USD | 47.78% |
| 2023 Q2 | 112 Million USD | -2.07% |
| 2022 Q4 | 77.39 Million USD | -17.83% |
| 2022 FY | - USD | -22.06% |
| 2022 Q1 | 92.56 Million EUR | 158.97% |
| 2022 Q2 | 82.67 Million EUR | -10.69% |
| 2022 Q3 | 94.18 Million USD | 13.92% |
| 2021 Q2 | 99.06 Million EUR | 19.48% |
| 2021 Q1 | 82.91 Million EUR | 41.32% |
| 2021 Q3 | 132.21 Million EUR | 33.46% |
| 2021 Q4 | 35.74 Million EUR | -72.96% |
| 2021 FY | - USD | 18.7% |
| 2020 Q4 | 58.67 Million EUR | -55.23% |
| 2020 FY | - USD | -7.46% |
| 2020 Q3 | 131.06 Million EUR | 135.56% |
| 2020 Q2 | 55.64 Million EUR | 8.31% |
| 2020 Q1 | 51.37 Million EUR | -82.55% |
| 2019 Q4 | 294.33 Million EUR | 164.09% |
| 2019 FY | - USD | 38.64% |
| 2019 Q2 | 93.04 Million EUR | -5.57% |
| 2019 Q1 | 98.53 Million EUR | 45.73% |
| 2019 Q3 | 111.45 Million EUR | 19.78% |
| 2018 Q2 | 65.74 Million EUR | -9.26% |
| 2018 Q4 | 67.61 Million EUR | -25.88% |
| 2018 FY | - EUR | 1.5% |
| 2018 Q1 | 72.45 Million EUR | 18.45% |
| 2018 Q3 | 91.21 Million EUR | 38.74% |
| 2017 Q3 | 86.81 Million EUR | 18.33% |
| 2017 FY | - EUR | 3.27% |
| 2017 Q1 | 71.19 Million EUR | 5.72% |
| 2017 Q2 | 73.36 Million EUR | 3.05% |
| 2017 Q4 | 61.16 Million EUR | -29.54% |
| 2016 FY | - EUR | 1.11% |
| 2016 Q3 | 80.08 Million EUR | 10.78% |
| 2016 Q2 | 72.29 Million EUR | 13.77% |
| 2016 Q4 | 67.34 Million EUR | -15.91% |
| 2016 Q1 | 63.54 Million EUR | 9.54% |
| 2015 Q3 | 86.55 Million EUR | 38.14% |
| 2015 FY | - EUR | 5.47% |
| 2015 Q4 | 58.01 Million EUR | -32.98% |
| 2015 Q1 | 72 Million EUR | 21.54% |
| 2015 Q2 | 62.65 Million EUR | -12.98% |
| 2014 Q4 | 59.24 Million EUR | -25.78% |
| 2014 Q3 | 79.82 Million EUR | 37.83% |
| 2014 Q1 | 67.92 Million EUR | 20.08% |
| 2014 Q2 | 57.91 Million EUR | -14.74% |
| 2014 FY | - EUR | 12.77% |
| 2013 FY | - EUR | 8.27% |
| 2013 Q3 | 69.35 Million EUR | 29.53% |
| 2013 Q2 | 53.54 Million EUR | -3.98% |
| 2013 Q1 | 55.76 Million EUR | 14.0% |
| 2013 Q4 | 56.56 Million EUR | -18.44% |
| 2012 Q3 | 63.05 Million EUR | 24.92% |
| 2012 Q1 | 55.13 Million EUR | 40.76% |
| 2012 Q4 | 48.91 Million EUR | -22.42% |
| 2012 Q2 | 50.47 Million EUR | -8.45% |
| 2012 FY | - EUR | 3.3% |
| 2011 FY | - EUR | 4.02% |
| 2011 Q4 | 39.16 Million EUR | -36.39% |
| 2011 Q3 | 61.57 Million EUR | 18.73% |
| 2011 Q2 | 51.86 Million EUR | -1.8% |
| 2011 Q1 | 52.81 Million EUR | 7.51% |
| 2010 Q2 | 51.02 Million EUR | 11.42% |
| 2010 Q4 | 49.12 Million EUR | -18.1% |
| 2010 Q3 | 59.98 Million EUR | 17.57% |
| 2010 FY | - EUR | 2.43% |
| 2010 Q1 | 45.79 Million EUR | -6.13% |
| 2009 Q2 | 46.01 Million EUR | 14.77% |
| 2009 Q3 | 54.83 Million EUR | 19.17% |
| 2009 Q4 | 48.78 Million EUR | -11.04% |
| 2009 FY | - EUR | 5.74% |
| 2009 Q1 | 40.09 Million EUR | 0.0% |
| 2008 FY | - EUR | 13.47% |
| 2007 FY | - EUR | -47.8% |
| 2006 FY | - EUR | -46.97% |
| 2005 FY | - EUR | 967.71% |
| 2004 FY | - EUR | -21.4% |
| 2003 FY | - EUR | 6.34% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 41990.381% |
| Ansell Limited | 209.86 Million USD | -92.415% |
| Ansell Limited | 206.3 Million USD | -95.736% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -842.591% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 24950.226% |
| Psykey, Inc. | -1.29 Million USD | 31274.458% |
| ConvaTec Group Plc | 455.5 Million USD | 11.349% |
| ConvaTec Group Plc | 455.5 Million USD | 11.349% |
| Encision Inc. | -544.19 Thousand USD | 74302.078% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 284850.018% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 367428.3% |
| Innovative MedTech Inc. | -7.67 Million USD | 5362.101% |
| LifePoint, Inc. | -14.2 Million USD | 2943.262% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 6626.653% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 124347.385% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 187711.623% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 99612.056% |
| SmileDirectClub, Inc. | -186.13 Million USD | 316.937% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 9.83% |
| SheerVision, Inc. | -110.53 Thousand USD | 365430.993% |
| United Health Products, Inc. | -2.5 Million USD | 16237.868% |
| Vasamed, Inc. | -4.57 Million USD | 8927.394% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 17961.617% |
| Yubo International Biotech Limited | -1.17 Million USD | 34387.917% |